期刊
JOURNAL OF INFECTIOUS DISEASES
卷 222, 期 12, 页码 1960-1964出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiaa593
关键词
primary immunodeficiency; SARS-CoV-2; SARS coronavirus 2 antibody titer; neutralizing antibodies; COVID-19; intravenous immunoglobulin; plasma
资金
- Baxter AG, part of the Takeda group of companies, Vienna, Austria
The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is unclear. The question is particularly relevant for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 intravenous immunoglobulin preparations, produced from plasma collected in Europe and the United States, confirmed highly potent neutralization of a seasonal coronavirus; however, no cross-neutralization of the new SARS-CoV-2 was seen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据